Yasodha Natkunam, M.D., Ph.D
Academic Appointments
- Professor - Med Center Line, Pathology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Department of Pathology 300 Pasteur Dr L235 MC 5324 Stanford, CA 94305 Tel Work (650) 725-9354 Fax (650) 725-7409Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-7211 Tel (650) 725-9354Alternate Contact Thelma Santa Maria Administrative Associate Email Tel Work 650-498-4987Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematopathology
- Pathology and Laboratory Medicine
- Anatomic Pathology
Administrative Appointments
- Associate Chair for Hematopathology, Stanford (2009 - present)
- Program Director, Hematopathology Fellowship, Stanford (2009 - present)
- Associate Chair for Faculty Development and Diversity, Stanford (2009 - present)
- Co-Director, Immunodiagnosis Laboratory, Stanford (2005 - present)
Professional Education
| Internship: | Stanford University School of Medicine CA (1996) |
| Residency: | Stanford University School of Medicine CA (2000) |
| Board Certification: | Anatomic Pathology, American Board of Pathology (1998) |
| Medical Education: | Mt. Sinai School of Medicine NY (1995) |
| PhD: | Mt.Sinai School of Medicine, Molecular Biology (1993) |
| AB: | Bryn Mawr College, Biology (1987) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
My laboratory studies the tissue expression pattern of proteins that are of potential interest for the diagnosis, prognostic stratification and therapy of patients with lymphoma and leukemia. We are currently investigating prognostic markers in diffuse large B-cell lymphoma such that risk groups can be better defined. We are also interested in the immunodiagnostic and molecular characterization of rare and aggressive hematopoietic tumors such as Natural Killer/T-cell lymphomas, histiocytic malignancies and childhood lymphomas.
Clinical Trials
- Recruiting Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
- Not Recruiting Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
- Not Recruiting Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
- Not Recruiting Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
- Not Recruiting Phase II Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia
Publications
- CD137 ligand is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications. Am J Surg Pathol. 2013; (2): 250-8
- Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun. 2013: 1338
- CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012; (3): 795-803
- Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. Ann Diagn Pathol. 2013; (3): 250-5
- Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients. Mod Pathol. 2013
- Indolent T-Lymphoblastic Proliferation (iT-LBP): A Review of Clinical and Pathologic Features and Distinction from Malignant T-Lymphoblastic Lymphoma. Adv Anat Pathol. 2013; (3): 137-40
Help
